ČESKÁ UROLOGIE / CZECH UROLOGY – 1 / 2020

41 PŘEHLEDOVÝ ČLÁNEK Ces Urol 2020; 24(1): 26–41 49. Hartman TR, Nicolas E, Klein‑Szanto A, et al. The role of the Birt‑Hogg‑Dubé protein in mTOR acti‑ vation and renal tumorigenesis. Oncogene 2009; 28(13): 1594–1604. 50. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018; 36(12): 1891–1898. 51. Křepelová A, Puchmajerová A, Vasovčák P, Chocholatý M. Birt‑Hogg‑Dubé syndrome. Klin Onkol. 2012; 25(Suppl): S18–20. 52. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt‑Hogg‑Dubé syndrome. Am J Surg Pathol. 2002; 26(12): 1542–1552. 53. He H, Trpkov K, Martinek P, et al. „High‑grade oncocytic renal tumor“: morphologic, immunohisto‑ chemical, and molecular genetic study of 14 cases. Virchows Arch. 2018; 473(6): 725–738. 54. Stamatakis L, Metwalli AR, Middelton LA, Marston Linehan W. Diagnosis and management of BHD­ ‑associated kidney cancer. Fam Cancer 2013; 12(3): 397–402. 55. Musil Z, Vícha A, Zelinka T, et al. Hereditary pheochromocytoma and paraganglioma. Klin Onkol. 2012; 25 Suppl: S21–26. 56. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008; 100(17): 1260–1262. 57. Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase‑deficient renal cell carci‑ noma with focus on clinical and pathobiological aspects. Pol J Pathol. 2016; 67(1): 3–7. 58. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a mor‑ phologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014; 38(12): 1588–1602. 59. Rednam SP, Erez A, Druker H, et al. Von Hippel‑Lindau and Hereditary Pheochromocytoma/Para‑ ganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017; 23(12): e68–e75. 60. Mester JL, Zhou M, Prescott N, Eng C. Papillary renal cell carcinoma is associated with PTEN hamar‑ toma tumor syndrome. Urology. 2012; 79(5): 1187.e1–7. 61. Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear‑cell renal cell carcinoma. Mol Cancer Res. 2013; 11(9): 1061–1071. 62. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013; 92(6): 974–980. 63. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism‑jaw tumour syndrome. J Intern Med. 2003; 253(6): 634–642. 64. Hora M, Hes O, Eret V, et al. Translokační renální karcinom Xp11.2 typu ASPL/TFE3. Ces Urol 2008; 12(3): 186–193.